Biologic therapies targeting cytokines downstream of NF-κB activation have shown efficacy in treating inflammatory bone diseases, including periodontitis.TNF-α inhibitors, such as adalimumab and infliximab, are widely used in inflammatory conditions. The gene discussed is NFKB1; the disease is periodontitis.